In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase ...

“In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson’s disease who are ...

Parkinson’s disease is a neurodegenerative disorder that causes a gradual loss of brain nerve cells, which produce a chemical messenger called dopamine. Dopamine relays signals throughout the brain ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This is the first economic evaluation of palonosetron. Although further research is needed to evaluate the economic impact of palonosetron-based regimens in a real-life context, the present ...

Purpose: The antiemetic effectiveness of ondansetron 8 mg i.v., ondansetron 32 mg i.v., and granisetron 10 µg/kg or 1 mg i.v. as prophylaxis in breast cancer patients receiving cyclophosphamide ...

Entering text into the input field will update the search result below Home page Seeking Alpha - Power to Investors Search for Symbols, analysts, keywords ...

As of 1:08:31 p.m. EDT. Market Open.

Neurology Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve patient ...